HK1136160A1 - Disintegrin variants and pharmaceutical uses thereof - Google Patents

Disintegrin variants and pharmaceutical uses thereof

Info

Publication number
HK1136160A1
HK1136160A1 HK10103274.9A HK10103274A HK1136160A1 HK 1136160 A1 HK1136160 A1 HK 1136160A1 HK 10103274 A HK10103274 A HK 10103274A HK 1136160 A1 HK1136160 A1 HK 1136160A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical uses
disintegrin variants
disintegrin
variants
pharmaceutical
Prior art date
Application number
HK10103274.9A
Other languages
English (en)
Inventor
Woei-Jer Chuang
Wen-Mei Fu
Tur-Fu Huang
Wenya Huang
Chih-Hsin Tang
Chiu-Yueh Chen
Original Assignee
Univ Nat Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan filed Critical Univ Nat Taiwan
Publication of HK1136160A1 publication Critical patent/HK1136160A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10103274.9A 2006-12-26 2010-03-30 Disintegrin variants and pharmaceutical uses thereof HK1136160A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87185406P 2006-12-26 2006-12-26
PCT/US2007/026125 WO2008088548A2 (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
HK1136160A1 true HK1136160A1 (en) 2010-06-25

Family

ID=39636522

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103274.9A HK1136160A1 (en) 2006-12-26 2010-03-30 Disintegrin variants and pharmaceutical uses thereof

Country Status (16)

Country Link
US (1) US7943728B2 (ru)
EP (2) EP2124548B1 (ru)
JP (3) JP5908666B2 (ru)
KR (1) KR20090108049A (ru)
CN (1) CN101677537B (ru)
AU (1) AU2007343734B2 (ru)
BR (1) BRPI0720636A2 (ru)
CA (1) CA2672091A1 (ru)
ES (1) ES2389697T3 (ru)
HK (1) HK1136160A1 (ru)
IL (1) IL199564A (ru)
MX (1) MX2009007065A (ru)
NZ (2) NZ577998A (ru)
RU (2) RU2477727C2 (ru)
TW (1) TWI392738B (ru)
WO (1) WO2008088548A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
CN101481412B (zh) * 2009-02-09 2011-08-10 吉林大学 一种具有抗肿瘤作用的多肽及其编码基因与应用
RU2547592C2 (ru) * 2009-07-20 2015-04-10 Нэйшнл Ченг Кунг Юниверсити ПОЛИПЕПТИДЫ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИНТЕГРИНА αvβ3, КОНЪЮГИРОВАННЫЕ С ВАРИАНТОМ ЧЕЛЕВЕЧЕСКОГО СЫВОРОТОЧНОГО АЛЬБУМИНА (HSA), И ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
US20120264212A1 (en) * 2009-11-06 2012-10-18 Virginia Tech Intellectual Properties, Inc. Compounds and methods for inhibiting the metastasis of cancer cells
US9044436B2 (en) * 2009-12-23 2015-06-02 National Cheng Kung University Compositions and methods for the treatment of angiogenesis-related eye diseases
CN103327996B (zh) * 2010-11-01 2016-06-15 延世大学校产学协力团 血栓溶解用组合物及包含其的血管狭窄或闭塞性疾病的治疗用药剂学组合物
WO2015016616A1 (ko) 2013-07-30 2015-02-05 연세대학교 산학협력단 삭사틸린-Ｆｃ 융합 단백질 및 이의 용도
KR101724129B1 (ko) * 2014-03-28 2017-04-10 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
TWI563001B (en) * 2014-08-22 2016-12-21 Univ Nat Cheng Kung Disintegrin variants and pharmaceutical uses thereof
US10463720B2 (en) 2014-12-31 2019-11-05 Huons Co., Ltd. Composition, containing RGD motif-containing peptide or fragment thereof, for treating burns and glaucoma, alleviating skin wrinkles, and promoting hair growth
CN104774247B (zh) * 2015-04-20 2018-06-05 中国药科大学 与整合素受体αvβ3相关的5肽
CA2987884C (en) * 2015-06-28 2023-01-03 Allgenesis Biotherapeutics Inc. Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease
WO2018048477A1 (en) * 2016-09-06 2018-03-15 Debina Diagnostics, Inc. Engineering and utility of fluorescent nanodiamond particles (ndp-f) for diagnostics and treatment of blood clots in human and veterinary medicine
US11085920B2 (en) 2016-09-06 2021-08-10 Debina Diagnostics, Inc. Nanodiamond particles and related devices and methods
EP3665190B1 (en) * 2017-08-09 2023-07-26 National Taiwan University Disintegrin variants and uses thereof
CA3144004A1 (en) * 2019-06-18 2020-12-24 Debina Diagnostics, Inc. Compositions and articles comprising (nano)diamond particles
BR102021016135A2 (pt) * 2021-08-16 2023-02-23 Novageia Biotecnologia Ltda Antagonistas miméticos macrocíclicos com atividade biológica, seus usos e composições
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0382451A3 (en) * 1989-02-07 1991-05-29 Merck & Co. Inc. Viper venom polypeptides and variants
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JPH05255395A (ja) * 1990-10-26 1993-10-05 Takeda Chem Ind Ltd ポリペプチドおよびその製造法
US5380646A (en) * 1992-10-19 1995-01-10 Temple University Of The Commonwealth System Of Higher Education Thrombus detection using radiolabelled disintegrins
US6710030B1 (en) 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
ATE464892T1 (de) * 2000-02-03 2010-05-15 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
WO2003104243A1 (en) * 2002-06-07 2003-12-18 Wisconsin Alumni Research Foundation Chemical synthesis of reagents for peptide coupling
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
EP2634252B1 (en) * 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases

Also Published As

Publication number Publication date
JP2016047818A (ja) 2016-04-07
EP2124548A2 (en) 2009-12-02
ES2389697T3 (es) 2012-10-30
CN101677537B (zh) 2016-08-17
BRPI0720636A2 (pt) 2014-01-07
WO2008088548A2 (en) 2008-07-24
JP2013151502A (ja) 2013-08-08
NZ577998A (en) 2012-03-30
TWI392738B (zh) 2013-04-11
AU2007343734B2 (en) 2014-01-30
CN101677537A (zh) 2010-03-24
KR20090108049A (ko) 2009-10-14
RU2012148887A (ru) 2014-05-27
IL199564A (en) 2015-05-31
AU2007343734A2 (en) 2009-09-03
RU2009128647A (ru) 2011-02-10
MX2009007065A (es) 2009-10-13
JP2010514444A (ja) 2010-05-06
EP2522676A2 (en) 2012-11-14
RU2477727C2 (ru) 2013-03-20
US7943728B2 (en) 2011-05-17
JP5908666B2 (ja) 2016-04-26
EP2522676A3 (en) 2013-02-27
AU2007343734A1 (en) 2008-07-24
TW200848070A (en) 2008-12-16
WO2008088548A3 (en) 2008-10-16
CA2672091A1 (en) 2008-07-24
EP2124548B1 (en) 2012-06-13
EP2124548A4 (en) 2010-05-05
NZ598176A (en) 2013-08-30
US20080188413A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
HK1136160A1 (en) Disintegrin variants and pharmaceutical uses thereof
IL194751A0 (en) Drugs and uses
ZA200810323B (en) Fkbp-l and uses thereof
ZA200902823B (en) Oligoribonucleotides and uses thereof
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
GB0606263D0 (en) Assay methods and devices
PL2064327T3 (pl) Dbait i ich zastosowania
IL198893A0 (en) Lipase variants for pharmaceutical use
EP2080242A4 (en) TOPOSCOPIC ACCESS AND ACCESS DEVICES
IL201019A0 (en) Asparaginase enzyme variants and uses thereof
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0516069D0 (en) Pharmaceutical and use thereof
HK1133552A1 (en) Carboranylporphyrins and uses thereof
IL193700A0 (en) Medicaments and proteins
HK1136819A1 (en) Novel dithiolopyrrolones and their therapeutic applications
IL193372A0 (en) Pharmaceutical composition comprising oseltamivir phosphate
IL193469A0 (en) Novel lipases and uses thereof
IL197883A0 (en) Combination drug
SI2001445T1 (sl) Farmacevtski sferoidi
ZA200807233B (en) Novel lipases and uses thereof
GB2444960B (en) Combined pseudoscope and hyperscope
GB0621665D0 (en) Blogmail and podmail
GB0622332D0 (en) Drug
GB0625433D0 (en) Pharmaceutical combinations
GB0614457D0 (en) Pharmaceutical Combinations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161221